Viral Oncogenesis in Humans

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Virology".

Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 8036

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacy, Center for Advanced Studies and Technology (CAST), “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
Interests: bacterial infections; viral infections; cancer; oncomodulatory effects of microbial infections; multi-drug resistance; metabolism; virus isolation, identification and genetic characterization; evolution of human pathogens; phylogenetic analysis of pathogens
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The molecular mechanisms of oncogenesis are complex and can be activated in stem cells by virus-induced genetic and epigenetic changes that lead to alterations in cellular homeostasis and interference with physiological developmental programs. While it is estimated that viruses account for almost 20% of all human cancer cases, only some tumor types are currently associated with a viral etiology. Cervical and genital squamous cell carcinomas are associated, in 99.7% of cases, with oncogenic strains of HPV, hepatocellular carcinoma is associated with HBV and HCV infections in about 80% of cases, and EBV is detected in almost all Burkitt’s lymphomas from endemic areas. On the other hand, only a minority of HTLV1 carriers develop T-cell lymphoma, and moreover, Merkel cell carcinoma and Kaposi’s sarcoma seem to be associated with MCPyV and KSHV principally in immunodeficient subjects. Future tumor virology may be able to demonstrate the oncogenic potential of other common infections that might contribute to the global tumor burden. This may be the case for HCMV, detected in several types of common tumors, including glioblastomas and breast and colorectal carcinomas.
Malignancy induced by viruses is influenced by a combination of viral, host, and environmental factors that are currently not fully understood. This Special Issue aims at an improved understanding of these complex interactions. Research articles or review articles on the topic are welcome.

• Oncogenic viruses
• Cancer
• Epigenetics
• Virus-host interactions
• Viral carcinogenesis

Fabio Verginelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Oncogenic viruses; Cancer; Epigenetics; Virus-host interactions; Viral carcinogenesis

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1130 KiB  
Article
Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
by Giuseppe Stragliotto, Mattia Russel Pantalone, Afsar Rahbar and Cecilia Söderberg-Nauclér
Microorganisms 2020, 8(10), 1471; https://doi.org/10.3390/microorganisms8101471 - 24 Sep 2020
Cited by 17 | Viewed by 2844
Abstract
Patients with glioblastoma have a very poor prognosis despite aggressive therapeutic strategies. Cytomegalovirus has been detected in >90% of glioblastoma tumors. This virus can affect tumor progression and may represent a novel glioblastoma therapy target. We report, here, a retrospective survival analysis of [...] Read more.
Patients with glioblastoma have a very poor prognosis despite aggressive therapeutic strategies. Cytomegalovirus has been detected in >90% of glioblastoma tumors. This virus can affect tumor progression and may represent a novel glioblastoma therapy target. We report, here, a retrospective survival analysis of patients with secondary glioblastoma who were treated with the anti-viral drug valganciclovir at Karolinska University Hospital in Stockholm. We performed survival analyses of eight patients with secondary glioblastoma who were treated with a standard dose of valganciclovir as an add-on to second-line therapy after their disease progression to glioblastoma. Thirty-six patients with secondary glioblastoma admitted during the same time period who received similar treatment and care served as contemporary controls. The patients treated with valganciclovir showed an increased median overall survival after progression to glioblastoma compared with controls (19.1 versus 12.7 months, p = 0.0072). This result indicates a potential positive effect of valganciclovir in secondary glioblastoma, which is in agreement with our previous observation that valganciclovir treatment improves the outcomes of patients with newly diagnosed glioblastoma. Larger randomized studies are warranted to prove this hypothesis. Full article
(This article belongs to the Special Issue Viral Oncogenesis in Humans)
Show Figures

Figure 1

Review

Jump to: Research

40 pages, 2673 KiB  
Review
Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis
by Shimaa Hassan AbdelAziz Soliman, Arturo Orlacchio and Fabio Verginelli
Microorganisms 2021, 9(6), 1179; https://doi.org/10.3390/microorganisms9061179 - 30 May 2021
Cited by 12 | Viewed by 4168
Abstract
Tumorigenesis due to viral infection accounts for a high fraction of the total global cancer burden (15–20%) of all human cancers. A comprehensive understanding of the mechanisms by which viral infection leads to tumor development is extremely important. One of the main mechanisms [...] Read more.
Tumorigenesis due to viral infection accounts for a high fraction of the total global cancer burden (15–20%) of all human cancers. A comprehensive understanding of the mechanisms by which viral infection leads to tumor development is extremely important. One of the main mechanisms by which viruses induce host cell proliferation programs is through controlling the host’s epigenetic machinery. In this review, we dissect the epigenetic pathways through which oncogenic viruses can integrate their genome into host cell chromosomes and lead to tumor progression. In addition, we highlight the potential use of drugs based on histone modifiers in reducing the global impact of cancer development due to viral infection. Full article
(This article belongs to the Special Issue Viral Oncogenesis in Humans)
Show Figures

Figure 1

Back to TopTop